Todd D. Armstrong

6.4k total citations · 1 hit paper
54 papers, 3.3k citations indexed

About

Todd D. Armstrong is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Todd D. Armstrong has authored 54 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Immunology, 39 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Todd D. Armstrong's work include Immunotherapy and Immune Responses (35 papers), Cancer Immunotherapy and Biomarkers (19 papers) and CAR-T cell therapy research (17 papers). Todd D. Armstrong is often cited by papers focused on Immunotherapy and Immune Responses (35 papers), Cancer Immunotherapy and Biomarkers (19 papers) and CAR-T cell therapy research (17 papers). Todd D. Armstrong collaborates with scholars based in United States, Croatia and Germany. Todd D. Armstrong's co-authors include Elizabeth M. Jaffee, Leisha A. Emens, Virginia K. Clements, Suzanne Ostrand‐Rosenberg, Theodore Kouo, Lanqing Huang, Alexandra B. Pucsek, Sara Solt, Lukas W. Pfannenstiel and Elizabeth A. Manning and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

Todd D. Armstrong

53 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells

2015 415 citations Theodore Kouo, Lanqing Huang et al. Cancer Immunology Research profile →

Peers

Countries citing papers authored by Todd D. Armstrong

Since Specialization

Citations

This map shows the geographic impact of Todd D. Armstrong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd D. Armstrong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd D. Armstrong more than expected).

Fields of papers citing papers by Todd D. Armstrong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Todd D. Armstrong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd D. Armstrong. The network helps show where Todd D. Armstrong may publish in the future.

Co-authorship network of co-authors of Todd D. Armstrong

This figure shows the co-authorship network connecting the top 25 collaborators of Todd D. Armstrong. A scholar is included among the top collaborators of Todd D. Armstrong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Todd D. Armstrong. Todd D. Armstrong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Fibroblasts in the Aged Pancreas Drive Pancreatic Cancer Progression 2024 ·Cancer Research ·Daniel J. Zabransky, Yash Chhabra, Mitchell E. Fane, (unknown), James M. Leatherman, Laura Hüser, Jacquelyn W. Zimmerman, Daniel Delitto, Song Han, Todd D. Armstrong, Soren Charmsaz, (unknown), (unknown), Elizabeth D. Thompson, Steven J. Hughes, Jennifer O’Connell, Josephine M. Egan, Elizabeth M. Jaffee, Ashani T. Weeraratna	13
2	CD4 T cell–activating neoantigens enhance personalized cancer vaccine efficacy 2023 ·JCI Insight ·Amanda L. Huff, (unknown), Jacob T. Mitchell, (unknown), Emily F. Davis-Marcisak, (unknown), Melissa R. Lyman, Rulin Wang, (unknown), (unknown), (unknown), James M. Leatherman, Mark Yarchoan, (unknown), Srinivasan Yegnasubramanian, Luciane T. Kagohara, Elana J. Fertig, Elizabeth M. Jaffee, Todd D. Armstrong, Neeha Zaidi	14
3	Nanoparticle interactions with immune cells dominate tumor retention and induce T cell–mediated tumor suppression in models of breast cancer 2020 ·Science Advances ·Preethi Korangath, James D. Barnett, Anirudh Sharma, Elizabeth Henderson, Jacqueline Stewart, Shu-Han Yu, Sri Kamal Kandala, Chun-Ting Yang, Julia S. Caserto, Mohammad Hedayati, Todd D. Armstrong, Elizabeth M. Jaffee, Cordula Gruettner, Xian Zhou, Wei Fu, Chen Hu, Saraswati Sukumar, Brian W. Simons, Robert Ivkov	131
4	Inhibition of miR-21 Regulates Mutant KRAS Effector Pathways and Intercepts Pancreatic Ductal Adenocarcinoma Development 2020 ·Cancer Prevention Research ·(unknown), Robert A. Anders, Elana J. Fertig, (unknown), Alexander C. Hopkins, Bridget P. Keenan, Aleksandra Popović, Todd D. Armstrong, Elizabeth M. Jaffee, Jacquelyn W. Zimmerman	15
5	A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell–Mediated Anticancer Activity 2019 ·Cancer Immunology Research ·S. Hayley, (unknown), Evanthia T. Roussos Torres, John-William Sidhom, Tara M. Robinson, Brian J. Christmas, Blake Scott, Kayla Cruz, Skylar Woolman, Valerie Wall, Todd D. Armstrong, Elizabeth M. Jaffee	94
6	Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer 2019 ·Clinical Cancer Research ·Alex B. Blair, Victoria M. Kim, Stephen Muth, May Tun Saung, Nathalie A. Lokker, Barbara Blouw, Todd D. Armstrong, Elizabeth M. Jaffee, Takahiro Tsujikawa, Lisa M. Coussens, Jin He, Richard A. Burkhart, Christopher L. Wolfgang, Lei Zheng	64
7	Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer 2018 ·JCI Insight ·(unknown), Alexander C. Hopkins, Eric R. Lutz, Annie A. Wu, Mark Yarchoan, Kayla Cruz, Skylar Woolman, Teena Vithayathil, Laura Hix Glickman, Chudi Ndubaku, Sarah M. McWhirter, Thomas W. Dubensky, Todd D. Armstrong, Elizabeth M. Jaffee, Neeha Zaidi	132
8	A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice 2017 ·Cancer Immunology Research ·Jeremy B. Foote, Marleen Kok, James M. Leatherman, Todd D. Armstrong, (unknown), Laureen S. Ojalvo, David B. Kanne, Elizabeth M. Jaffee, Thomas W. Dubensky, Leisha A. Emens	117
9	Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells breakdown → 2015 ·Cancer Immunology Research ·Theodore Kouo, Lanqing Huang, Alexandra B. Pucsek, (unknown), Sara Solt, Todd D. Armstrong, Elizabeth M. Jaffee	415
10	Nonviral Oncogenic Antigens and the Inflammatory Signals Driving Early Cancer Development as Targets for Cancer Immunoprevention 2015 ·Clinical Cancer Research ·(unknown), Todd D. Armstrong, Elizabeth M. Jaffee	37
11	Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells 2012 ·PLoS ONE ·Vivian Weiß, (unknown), Hong Song, Theodore Kouo, Chelsea M. Black, George Sgouros, Elizabeth M. Jaffee, Todd D. Armstrong	34
12	Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice 2010 ·Cellular Immunology ·Lukas W. Pfannenstiel, Samuel S.K. Lam, Leisha A. Emens, Elizabeth M. Jaffee, Todd D. Armstrong	124
13	CD8⁺Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti‐tumor response 2010 ·International Journal of Cancer ·Dung T. Le, Brian H. Ladle, Timothy Lee, Vivian Weiß, Xiaosai Yao, Ashley Leubner, Todd D. Armstrong, Elizabeth M. Jaffee	18
14	Antibody association with HER-2/neu–targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs 2008 ·Journal of Clinical Investigation ·Peter Kim, Todd D. Armstrong, Hong Song, Matthew E. Wolpoe, Vivian Weiß, Elizabeth A. Manning, Lan Huang, Satoshi Murata, George Sgouros, Leisha A. Emens, R. Todd Reilly, Elizabeth M. Jaffee	66
15	Effective Depletion of Regulatory T Cells Allows the Recruitment of Mesothelin‐Specific CD8⁺ T Cells to the Antitumor Immune Response Against a Mesothelin‐Expressing Mouse Pancreatic Adenocarcinoma 2008 ·Clinical and Translational Science ·(unknown), (unknown), Todd D. Armstrong, Elizabeth M. Jaffee	58
16	OX40 Costimulation Synergizes with GM-CSF Whole-Cell Vaccination to Overcome Established CD8+ T Cell Tolerance to an Endogenous Tumor Antigen 2006 ·The Journal of Immunology ·Satoshi Murata, Brian H. Ladle, Peter Kim, Eric R. Lutz, Matthew E. Wolpoe, Susan E. Ivie, Holly Smith, Todd D. Armstrong, Leisha A. Emens, Elizabeth M. Jaffee, R. Todd Reilly	79
17	Class II-Transfected Tumor Cells Directly Present Endogenous Antigen to CD4+ T Cells In Vitro and Are APCs for Tumor-Encoded Antigens In Vivo 1998 ·Journal of Immunotherapy ·Todd D. Armstrong, Virginia K. Clements, Suzanne Ostrand‐Rosenberg	31
18	Immunotherapy of Established Tumor with MHC Class II and B7.1 Cell-Based Tumor Vaccines 1998 ·Advances in experimental medicine and biology ·Suzanne Ostrand‐Rosenberg, Beth A. Pulaski, Todd D. Armstrong, Virginia K. Clements	9
19	Tumor antigen presentation: changing the rules 1998 ·Cancer Immunology Immunotherapy ·Todd D. Armstrong, Beth A. Pulaski, (unknown)	38
20	Invariant chain alters the malignant phenotype of MHC class II+ tumor cells 1992 ·The Journal of Immunology ·Virginia K. Clements, Sivasubramanian Baskar, Todd D. Armstrong, Suzanne Ostrand‐Rosenberg	56

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact